Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux

Regulatory News:

Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO):

Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, the following resources were listed in the liquidity account as at December 31, 2019, settlement date:

• 341,069 shares
• €13,897.05 in cash

During the 2^nd half of 2019, were negotiated a total of:

BUY		510,522 shares		€327,615.49		656 executions
SALE		380,311 shares		€246,522.48		525 executions

It is recalled that for the last half-year summary as at June 30, 2019, the following resources were included in the liquidity account:

• 210,858 shares
• €95,092.53 in cash

During the 1^st half of 2019, were negotiated a total of:

BUY		551,475 shares		€486,463.73		866 executions
SALE		451,712 shares		€404,963.46		711 executions

It is also recalled that when the contract was set up on December 3, 2018, the following resources had been allocated to the liquidity account:

• 87,612 shares
• €196,423.24 in cash

The liquidity agreement complies with AMF Decision n° 2018-01 dated 2^nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA, the first compound from platON, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

OX401 is a new drug candidate from platON, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

Onxeo’s portfolio also includes belinostat, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2^nd line treatment for patients with peripheral T cell lymphoma and marketed in the US under the name Beleodaq (belinostat IV form).

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.7.1.4 “Risk Factors” ("Facteurs de Risque") of the 2018 registration document filed with the Autorité des marchés financiers on April 25, 2019 under number D.19-0282, which is available on the Autorité des marchés financiers website (www.amf-france.org) or on the Company’s website (www.onxeo.com).

APPENDIX

		Buy Side						Sell Side
		Number of executions		Number of shares		Traded volume in EUR		Number of executions			Number of shares		Traded volume in EUR
Total		656		510,522		327,615.49		525			380,311		246,522.48
01/07/2019		4		4,000		3,160.00		42			28,493		22,794.40
02/07/2019		3		2,000		1,580.00		3			2,001		1,620.81
08/07/2019		4		3,000		2,370.00		-			-		-
09/07/2019		8		6,001		4,680.78		1			1		0.79
10/07/2019		6		5,000		3,850.00		-			-		-
11/07/2019		2		1,001		770.77		4			2,001		1,560.78
12/07/2019		5		4,250		3,272.50		2			1,004		783.12
15/07/2019		3		751		578.27		1			1		0.77
16/07/2019		2		2,000		1,520.00		1			749		576.73
18/07/2019		22		17,296		12,972.00		1			1		0.76
19/07/2019		4		1,705		1,261.70		2			275		206.25
22/07/2019		11		9,000		6,570.00		1			1		0.73
23/07/2019		6		5,922		4,204.62		18			9,999		7,299.27
24/07/2019		3		2,000		1,460.00		5			2,422		1,792.28
25/07/2019		2		958		728.08		29			22,304		16,951.04
26/07/2019		20		16,043		12,032.25		-			-		-
29/07/2019		2		1,000		740.00		-			-		-
30/07/2019		4		3,001		2,190.73		1			1		0.74
01/08/2019		9		6,000		4,320.00		-			-		-
02/08/2019		4		2,078		1,475.38		-			-		-
05/08/2019		14		12,000		8,520.00		2			1,000		710.00
06/08/2019		1		144		100.80		2			1,000		710.00
07/08/2019		7		6,856		4,799.20		-			-		-
08/08/2019		11		4,000		2,800.00		-			-		-
09/08/2019		18		29,001		20,300.70		16			19,850		14,292.00
12/08/2019		11		9,946		6,862.74		3			3,000		2,100.00
13/08/2019		21		16,317		11,095.56		14			9,047		6,332.90
14/08/2019		23		18,738		12,929.22		28			19,155		13,600.05
15/08/2019		22		24,000		15,840.00		-			-		-
16/08/2019		2		2,000		1,300.00		12			10,000		6,700.00
19/08/2019		-		-		-		8			7,000		4,760.00
20/08/2019		1		491		333.88		5			4,000		2,760.00
21/08/2019		5		4,000		2,760.00		5			4,000		2,800.00
22/08/2019		5		3,509		2,386.12		-			-		-
23/08/2019		7		5,001		3,350.67		4			2,201		1,496.68
26/08/2019		2		1,000		670.00		-			-		-
27/08/2019		2		186		124.62		1			1		0.67
28/08/2019		1		1		0.68		1			1		0.68
29/08/2019		11		6,125		4,042.50		-			-		-
30/08/2019		6		2,690		1,748.50		-			-		-
02/09/2019		3		3,000		1,980.00		11			7,015		4,700.05
03/09/2019		8		4,355		2,874.30		-			-		-
04/09/2019		2		645		419.25		-			-		-
05/09/2019		1		1,000		650.00		-			-		-
06/09/2019		3		2,001		1,300.65		1			1		0.65
09/09/2019		6		3,000		1,920.00		-			-		-
10/09/2019		6		6,000		3,840.00		12			9,000		5,940.00
11/09/2019		6		4,000		2,560.00		-			-		-
12/09/2019		17		22,999		14,259.38		-			-		-
13/09/2019		-		-		-		7			5,000		3,150.00
16/09/2019		-		-		-		1			1,000		630.00
17/09/2019		11		9,245		5,824.35 6				5,374			3,439.36
18/09/2019		12		6,755		4,188.10		5		4,000			2,520.00
19/09/2019		4		3,000		1,950.00		35		30,411			20,375.37
20/09/2019		18		15,000		9,450.00		-		-			-
23/09/2019		5		5,000		3,100.00		-		-			-
24/09/2019		1		1,000		610.00		-		-			-
25/09/2019		4		3,000		1,830.00		-		-			-
26/09/2019		1		81		49.41		-		-			-
27/09/2019		7		4,920		3,001.20		1		1			0.61
30/09/2019		1		1,000		600.00		2		1,254			777.48
01/10/2019		2		6,000		3,600.00		1		746			462.52
02/10/2019		2		2,000		1,200.00		-		-			-
03/10/2019		7		9,000		5,310.00		-		-			-
04/10/2019		2		1,592		923.36		-		-			-
07/10/2019		4		2,408		1,348.48		-		-			-
08/10/2019		1		1,000		540.00		-		-			-
09/10/2019		1		1		0.54		1		1			0.54
10/10/2019		1		1,000		530.00		-		-			-
11/10/2019		1		1,000		520.00		-		-			-
14/10/2019		3		2,000		1,000.00		-		-			-
15/10/2019		-		-		-		8		7,000			3,920.00
16/10/2019		-		-		-		14		12,000			7,200.00
17/10/2019		1		2,000		1,160.00		-		-			-
18/10/2019		1		1,000		560.00		-		-			-
21/10/2019		21		14,000		7,840.00		1		1,000			560.00
22/10/2019		1		1		0.55		1		1			0.55
23/10/2019		-		-		-		13		13,000			7,410.00
24/10/2019		13		8,301		4,648.56		2		376			214.32
25/10/2019		10		3,700		1,998.00		-		-			-
28/10/2019		2		2,000		1,080.00		-		-			-
29/10/2019		1		1		0.54		1		1			0.54
30/10/2019		-		-		-		1		1,000			550.00
31/10/2019		5		2,001		1,060.53		1		1			0.55
01/11/2019		3		2,001		1,040.52		5		3,672			1,982.88
04/11/2019		-		-		-		5		1,329			717.66
05/11/2019		3		3,000		1,650.00		5		4,000			2,240.00
06/11/2019		6		5,000		2,750.00		8		6,625			3,710.00
07/11/2019		6		3,000		1,650.00		2		1,001			560.56
08/11/2019		-		-		-		3		999			559.44
11/11/2019		1		1,000		550.00		1		1			0.56
12/11/2019		2		2,000		1,100.00		2		1,999			1,119.44
13/11/2019		8		6,000		3,300.00		10		7,963			4,459.28
14/11/2019		13		9,525		5,524.50		44		31,528			18,601.52
15/11/2019		18		14,475		8,250.75		-		-			-
18/11/2019		2		2,000		1,120.00		-		-			-
19/11/2019		14		8,152		4,646.64		15		15,000			8,700.00
20/11/2019		10		6,848		3,834.88		1		1,000			560.00
21/11/2019		3		3,000		1,650.00		1		1,000			570.00
22/11/2019		2		2,000		1,100.00		7		3,000			1,650.00
25/11/2019		2		2,000		1,100.00		8		2,545			1,425.20
26/11/2019		8		4,454		2,449.70		5		3,455			1,934.80
27/11/2019		4		1,929		1,060.95		1		1			0.56
28/11/2019		1		1		0.55		3		2,001			1,120.56
29/11/2019		6		4,100		2,255.00		1		500			275.00
02/12/2019		3		2,517		1,359.18		-		-			-
03/12/2019		1		1		0.53		1		1			0.53
04/12/2019		12		5,001		2,650.53		1		1			0.53
05/12/2019		3		2,000		1,040.00		5		2,500			1,325.00
06/12/2019		1		500		265.00		4		4,000			2,160.00
09/12/2019		6		3,605		1,910.65		1		1			0.55
10/12/2019		2		1,395		725.40		-		-			-
11/12/2019		1		1		0.52		1		1			0.52
12/12/2019		8		5,463		2,950.02		19		15,588			8,573.40
13/12/2019		3		3,000		1,620.00		-		-			-
16/12/2019		3		2,489		1,344.06		-		-			-
17/12/2019		5		3,168		1,679.04		-		-			-
18/12/2019		2		1,880		977.60		-		-			-
19/12/2019		-		-		-		2		1,000			540.00
23/12/2019		2		2,000		1,040.00		-		-			-
27/12/2019		1		1,000		510.00		-		-			-
30/12/2019		-		-		-		1		1,000			530.00
31/12/2019		2		2,000		1,080.00		26		20,910			11,500.50

A Public Limited Company with Share Capital of 12,683,913.25 euros
Registered Address 49, boulevard du Général Martial Valin – 75015 Paris
Paris Trade and Companies’ Register 410 910 095

View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005741/en/